The catalogue
The claims, compound by compound
The field looks different once weight change, mortality, blood hormones and desire stop competing for the same headline.
The ambitions alongside the results
I cannot rank semaglutide, thymosin, CJC-1295, NAD+ and PT-141 as if they were rival treatments. They concern different problems, and their studies count different things. This catalogue is the comparison that seems worthwhile: how far each ambition has travelled into a direct test.
| Subject | What the published results establish |
|---|---|
| Semaglutide | Weight change in STEP 1, cardiovascular outcomes in SELECT and the kidney composite in FLOW concern distinct patient groups. |
| Thymosin Alpha-1 | TESTS found no significant 28-day survival benefit in adults with sepsis. Immune-cell effects remain a separate part of the literature. |
| CJC-1295 | Early healthy-adult work established prolonged growth-hormone and IGF-1 elevations. Sleep, recovery and muscle benefits await direct clinical proof. |
| NAD+ | Oral NR raised blood NAD+; a small NMN trial improved muscle insulin sensitivity. Human longevity remains unproved. |
| PT-141 | RECONNECT found average gains in desire and reduced desire-related distress in premenopausal women with HSDD. |
The differences are the substance of the story. A laboratory marker can be a useful result in its own right. A claim about surviving illness or functioning better has to carry that additional burden.
Approval and the actual preparation
Semaglutide and bremelanotide have approved medicines with specified uses. Thymalfasin has approvals abroad and lacks United States marketing approval. CJC-1295 is not approved for human use. NAD+ has no drug approval, and most controlled evidence discussed here concerns oral precursors.
The bremelanotide label and semaglutide safety review illustrate how benefit, adverse effects and a defined clinical use fit together. A different preparation with the same ingredient name has its own quality and evidence questions.
The next expansion worth testing
Direct measures of sleep and recovery would come first on my CJC-1295 research agenda. For NAD+ precursors, longer studies of daily function and measurements within tissues would address gaps identified by the human clinical review. For thymosin, the question needs to name the illness after the large null sepsis result.
Ambition is useful when it produces a precise experiment. After all those expanding claims, I would happily settle for a clear answer about one of them.